|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor is a major pro-inflammatory cytokine which triggers various physiological consequences by binding to and trimerizing its receptors, and has been the single most sought-after drug target for intervening autoimmune diseases such as rheumatoid arthritis and psoriasis.
|
29743640 |
2018 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor necrosis factor alpha (TNF-α) expression amplifies to excess amounts in several disorders such as rheumatoid arthritis and psoriasis.
|
29881431 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) inhibitors also retain a place in the management of psoriasis, with records of long-term safety.
|
30016379 |
2018 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor inhibitors decrease the risk of cardiovascular events in moderate to severe psoriasis, but the association between their effects on endothelial function and those on skin lesions has not been well studied.
|
30168849 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF inhibitors for psoriasis.
|
30215629 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α is a key cytokine for both hepatitis C progression and psoriasis.
|
30398009 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α Inhibitor-Induced psoriasis: A decade of experience at the Cleveland Clinic.
|
30576759 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor α inhibitors may be the drug of choice in patients with both psoriasis and sickle cell disease.
|
30893386 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) α which releases from keratinocytes activates dendritic cells in the early stages of complex pathogenesis of psoriasis.
|
30972872 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)‑α‑stimulated HaCaT cells and an imiquimod‑induced psoriasis mouse model were used to produce in vitro and in vivo models, respectively.
|
31017270 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings.
|
31094242 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
|
31240749 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF inhibitors are also efficacious for other inflammatory joint and spine diseases, and have been approved for inflammatory bowel disease, uveitis and psoriasis.
|
31639514 |
2019 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TNF-α -238 G/A, -308 G/A and -857 C/T polymorphisms could be used to identity individuals with elevated susceptibility to psoriasis in certain populations.
|
31775137 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Greek multicenter collaboration was established to recruit a cohort of patients (n = 80) with psoriasis treated with anti-TNF drugs.
|
22111980 |
2012 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant increase in PASI 75 (RR: 11.65; 95% CI: 9.01-15.06), PASI 90 (RR: 21.74; 95% CI: 14.28-33.10), PASI 100 (RR: 31.56; 95% CI: 14.66-67.96), PGA 0/1 (OR: 23.21; 95% CI: 14.61-36.89), and DLQI 0/1 (RR: 10.29; 95% CI: 7.52-14.09) was identified for anti-IL-23p19 mAb vs. placebo, and PASI 75 (RR: 1.25; 95% CI: 1.18-1.32), PASI 90 (OR: 2.56; 95% CI: 2.13-3.09), PASI 100 (OR: 2.38, 95% CI: 1.89-2.99), and DLQI 0/1 (RR: 1.33; 95% CI: 1.20-1.47) vs. tumour necrosis factor (TNF) antagonists for the treatment of psoriasis.
|
31389789 |
2019 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A subsequent clinical trial evaluated infliximab in a patient with CD and psoriasis, another disease in which increased levels of tumor necrosis factor-alpha are seen in lesions.
|
12789169 |
2003 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Activation of keratinocyte protein kinase C zeta in psoriasis plaques.
|
18385757 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adalimumab (ADA) is one of the tumor necrosis factor (TNF)-α monoclonal antibodies used for the treatment of psoriasis.
|
30672612 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adalimumab is an anti-TNF biologic drug that is efficacious in the treatment of psoriasis.
|
27538000 |
2016 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, cytokines such as TNF-α, IL-17A, and other immune pathways are the common links between the pathogenesis of psoriasis and atherosclerosis, and hence the approved treatments for psoriasis, which include selective cytokine inhibition (e.g., anti-TNF, anti-IL-17A, and anti-IL-12/23) and immune modulation (e.g., methotrexate or cyclosporine), provide an opportunity to examine the effect of modulating these pathways on atherogenesis.
|
28258057 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, the effects of the anti-TNFα drug Etanercept on metabolic profiles were investigated in patients with severe psoriasis.
|
25361234 |
2015 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Agents that block inflammatory pathways other than tumor necrosis factor (TNF) have represented new options for treating psoriasis in recent years.
|
28271735 |
2017 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
All drugs inhibited tumor necrosis factor alpha-induced nuclear factor kappa B activity in vitro, suggesting they might be effective for treating psoriasis in humans.
|
28643328 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although IL-17A and TNFα are effective therapeutic targets in psoriasis, IL-36 has recently emerged as a proinflammatory cytokine.
|
30224457 |
2018 |